Mp34-16 Disparities in Precision Medicine and Genetic Testing in Patients With Urologic Cancers

You have accessJournal of UrologyDiversity, Equity & Inclusion: Health Equity & Outcomes II (MP34)1 May 2024MP34-16 DISPARITIES IN PRECISION MEDICINE AND GENETIC TESTING IN PATIENTS WITH UROLOGIC CANCERS Sarosh Irani, Avinash Maganty, Kristian Stensland, Lindsey Herrel, and Rishi Sekar Sarosh IraniSarosh Irani , Avinash MagantyAvinash Maganty , Kristian StenslandKristian Stensland , Lindsey HerrelLindsey Herrel , and Rishi SekarRishi Sekar View All Author Informationhttps://doi.org/10.1097/01.JU.0001008876.78012.90.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: As precision medicine plays a growing role in cancer care, genetic testing is increasingly utilized in the management of patients with urologic cancers. Ensuring equitable access to precision medicine and genetic testing is essential to reduce disparities and deliver optimal cancer care. For these reasons, we evaluated disparities in knowledge and utilization of precision medicine and genetic testing in patients with urologic cancers. METHODS: We performed a cross-sectional analysis of the 2021 Health Information National Trends – Surveillance, Epidemiology, and End Results (HINTS-SEER) survey, a nationally representative survey of cancer survivors. We identified 348 patients with urologic cancers (282 prostate, 25 bladder, 41 kidney), representing a weighted population of approximately 100,000 patients. The primary outcomes of interest included awareness of precision medicine, discussion of genetic testing with their provider, and receipt of genetic testing, all of which are binary variables (yes/no). Independent variables included age, sex, race/ethnicity, education, and income. We performed a survey-weighted bivariate analysis. RESULTS: On survey-weighted analysis, 26.5% of patients were aware of precision medicine, 7.9% had discussed genetic testing with their provider, and 6.0% received genetic testing as part of their treatment plan. A greater proportion of patients aware of precision medicine/genetic testing were younger, male, Black, of higher education level, and of higher income level (all, p<0.05) (Figure 1). Similar associations of race/ethnicity, sex, education level, and income level with discussion and receipt of genetic testing/precision medicine were observed, however these were not statistically significant, likely due to small sample size. CONCLUSIONS: Significant disparities exist in awareness, discussion, and receipt of precision medicine and genetic testing in patients with urologic cancers. As the management of cancer increasingly utilizes precision medicine techniques, we must ensure equitable adoption for all patients with cancer. Download PPT Source of Funding: Rishi Sekar received research support from the National Cancer Institute institutional training grant T32-CA-236621 © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e577 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sarosh Irani More articles by this author Avinash Maganty More articles by this author Kristian Stensland More articles by this author Lindsey Herrel More articles by this author Rishi Sekar More articles by this author Expand All Advertisement PDF downloadLoading ...